Company Overview
Addex Therapeutics Ltd operates as a biotechnology company within the healthcare sector, specifically focusing on the discovery, development, and commercialization of small-molecule pharmaceutical products designed to treat neurological disorders. The firm's strategic emphasis lies in the discovery of G-protein coupled receptors and enzymes, with its lead program, Dipraglurant, currently progressing through phase 1 clinical trials in Switzerland. This enterprise maintains a market capitalization of $8.25M and reports annual revenue of $158,538, employing a workforce of just 2 individuals. These valuation and revenue figures indicate that the company occupies a highly niche position in the market, characterized by a small-scale operational footprint relative to its capitalization. The disparity between the substantial market cap and minimal revenue suggests that the market places significant value on the potential of its drug pipeline rather than current cash flows. The limited employee count further underscores the asset-light nature of the biotechnology business model at this stage of development.
Financial Health
The company reported revenue of $158,538 for the trailing twelve months, accompanied by a net income of $-6,198,837 and an EBITDA of $-2,456,840. The significant gap between the positive revenue figure and the substantial net loss reveals a cost structure dominated by research and development expenses, which is typical for early-stage pharmaceutical companies but indicates high burn rates. Free cash flow stands at $-599,840, meaning the company is consuming cash reserves to fund its operations and clinical trials rather than generating liquidity. The gross margin is recorded at 0.0%, while the operating margin is -1403.6% and the profit margin is also 0.0%, reflecting the heavy cost of goods sold and operational expenses relative to current sales volumes. On the balance sheet, the company holds $2.19M in cash against $36,549 in debt, supported by a debt-to-equity ratio of 0.61, which suggests a leveraged position relative to equity but low absolute leverage. The current ratio of 2.01 indicates that the company possesses sufficient short-term assets to cover its short-term liabilities, providing a buffer for liquidity management despite the negative earnings. Return on equity is -72.8% and return on assets is -15.9%, metrics that reveal management is currently generating negative returns on the capital invested, a common characteristic for pre-revenue biotechnology firms.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of positive earnings, while the forward P/E is listed as -134.00, implying that the market is pricing in future earnings recovery that has not yet materialized in historical data. The price-to-book ratio stands at 104.42, indicating that the market values the company at a significant premium over its book value, likely driven by intangible assets such as intellectual property and pipeline potential. Alternative valuation metrics include a price-to-sales ratio of 52.07 and an EV/EBITDA of -317.02, which suggest that traditional profitability-based valuation models are not applicable and that investors are focusing on revenue potential and asset value. The stock has traded between a 52-week high of $12.05 and a 52-week low of $5.57, placing the current market price within this specific volatility range. The beta value is 1.91, which indicates that the stock price is significantly more volatile than the broader market, moving approximately 91% more than the market index in response to general market movements.
Growth & Income
Revenue growth year-over-year is -15.0%, while earnings growth is N/A due to the company's lack of positive net income, meaning earnings are not growing in a traditional sense but are instead reflecting deep losses. As the company does not pay dividends, there is no dividend yield or payout ratio to evaluate for sustainability; instead, the firm operates by reinvesting all available resources, including its cash reserves, back into growth initiatives like clinical trials and drug discovery. Consequently, the overall growth and income profile is defined by negative revenue growth and zero income distribution, relying entirely on the successful commercialization of future products to shift the financial trajectory. This profile highlights a high-risk, high-potential growth strategy where immediate financial returns are sacrificed for long-term asset development in the neurological disorder space.